Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.32 |
| ▸ | FEN1 | P39748 | 3/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2394132 | 0.90 | AGTR2 (0.38) | AGTR1AGTR2 | |
| SCHEMBL3261878 | 0.85 | OPRM1 (0.36) | OPRM1OPRK1ALOX5APFEN1AGTR1 | |
| SCHEMBL2394000 | 0.85 | AGTR1 (0.40) | AGTR1 | |
| SCHEMBL2391983 | 0.82 | MME (0.31) | AGTR1 | |
| SCHEMBL2392342 | 0.74 | PYGL (0.34) | OPRM1OPRK1 | |
| SCHEMBL3264923 | 0.74 | AGTR2 (0.44) | AGTR1AGTR2 | |
| SCHEMBL2390362 | 0.72 | AGTR1 (0.38) | AGTR1 | |
| SCHEMBL652709 | 0.70 | MME (0.36) | AGTR2 | |
| SCHEMBL2391209 | 0.69 | — | — | |
| SCHEMBL2390358 | 0.69 | AGTR1 (0.48) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230525-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230525-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | OPRM1 344/4885OPRK1 173/4885ALOX5AP 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.